BTG Pactual Global Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-9,939
Closed -$513K 55
2018
Q3
$513K Sell
9,939
-19,959
-67% -$938K 0.21% 38
2018
Q2
$1.25M Buy
29,898
+1,236
+4% +$54.8K 0.36% 39
2018
Q1
$1.26M Buy
28,662
+3,434
+14% +$174K 0.34% 38
2017
Q4
$1.27M Buy
25,228
+853
+3% +$46.8K 0.46% 31
2017
Q3
$1.24M Sell
24,375
-1,013
-4% -$53.1K 0.39% 39
2017
Q2
$1.29M Buy
25,388
+5,743
+29% +$267K 0.37% 44
2017
Q1
$790K Buy
+19,645
New +$882K 0.29% 50
2016
Q2
Sell
-5,165
Closed -$209K 51
2016
Q1
$209K Buy
+5,165
New +$210K 0.51% 34

Other funds holding IONS

BTG Pactual Global Asset Management's IONS Position: Q4 2018 in Review

BTG Pactual Global Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2018, closing a stake of 9,939 shares — an estimated $513K sold.

BTG Pactual Global Asset Management first reported a position in IONS in Q1 2016 and held it in 8 quarters. The position peaked at $1.29M in Q2 2017. 329 funds tracked by Wall St. Rank hold IONS as of Q4 2018.

  • BTG Pactual Global Asset Management reported no remaining Ionis Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • BTG Pactual Global Asset Management sold 9,939 Ionis Pharmaceuticals shares in Q4 2018, an estimated $513K.
  • BTG Pactual Global Asset Management first reported a position in Ionis Pharmaceuticals in Q1 2016 and held it in 8 quarters.
  • BTG Pactual Global Asset Management's Ionis Pharmaceuticals position peaked at $1.29M in Q2 2017.
  • 329 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2018.

Based on BTG Pactual Global Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.